The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome
Open accessAbstract
Background Structural and functional neuroimaging studies suggest abnormal activity in the striatum of patients with the fragile X syndrome (FXS), the most common form of inherited mental retardation.Methods Neurophysiological and immunofluorescence experiments in striatal brain slices. We studied the synaptic transmission in a mouse model for FXS, as well as the subcellular localization of fragile X mental retardation protein (FMRP) and brain cytoplasmic (BC1) RNA in striatal axons.Results Our results show that absence of FMRP is associated with apparently normal striatal glutamate-mediated transmission, but abnormal gamma-aminobutyric acid (GABA) transmission. This effect is likely secondary to increased transmitter release from GABAergic nerve terminals. We detected the presence of FMRP in axons of striatal neurons and observed a selective increase in the frequency of spontaneous and miniature inhibitory postsynaptic currents (sIPSCs, mIPSCs) in fmr1-knockout mice. We also observed reduced paired-pulse ratio of evoked IPSCs, a finding that is consistent with the idea that transmitter release probability from striatal GABAergic nerve terminals is higher than normal in these mutants. Finally, we have identified the small noncoding BC1 RNA as a critical coplayer of FMRP in the regulation of striatal synaptic transmission.Conclusions Understanding the physiologic action of FMRP and the synaptic defects associated with GABA transmission might be useful to design appropriate pharmacologic interventions for FXS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GABA receptor system has also been reported as downregulated in FXS, partially due to destabilization of the mRNAs encoding the GABA receptor subunits (76,80,113).”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [76]
Experimental — accuracy not yet measuredIn the citing paper
“FMRP activity is regulated in response to metabotropic glutamate receptors (mGluRs) (78), 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid (AMPA) receptors (79), γ-aminobutyric acid (GABA) receptors (76,80,81), N-methyl-d-aspartate (NMDA) receptors (82)(83)(84), and the tyrosine kinase or BDNF/NT-3 growth factor (TrkB) receptors (85).”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [76]
In the citing paper
“Furthermore, extensive electrophysiological studies in the Fmr1 KO mouse model indicated an excitation/inhibition (glutamate/GABA; see below) imbalance (75)(76)(77).”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Instability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Brown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,108
Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function
Darnell, J. C., Jensen, K. B., Jin, P., Brown, V., Warren, S. T., & Darnell, R. B. (2001) · Cell · doi:10.1016/s0092-8674(01)00566-9 · Cited by 952
Inhibitory control of neostriatal projection neurons by GABAergic interneurons
Koós, T. Z., & Tepper, J. M. (1999) · Nature Neuroscience · doi:10.1038/8138 · Cited by 863
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676
Self-citationNeuronal RNA Granules: Movers and Makers
Kiebler, M. A., & Bassell, G. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.021 · Cited by 595
Krichevsky, A. M., & Kosik, K. S. (2001) · Neuron · doi:10.1016/s0896-6273(01)00508-6 · Cited by 536
Wilson, C. J., & Groves, P. M. (1980) · The Journal of Comparative Neurology · doi:10.1002/cne.901940308 · Cited by 527
Cited by
Sorted by citations
Interneuron dysfunction in psychiatric disorders
Marín, O. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3155 · Cited by 1,190
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
The Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
Self-citationMolecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528
Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders
Lee, E., Lee, J., & Kim, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.011 · Cited by 468
GABA system dysfunction in autism and related disorders: From synapse to symptoms
Coghlan, S., Horder, J., Inkster, B., Méndez, M. A., Murphy, D., & Nutt, D. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.005 · Cited by 459
Altered Neuronal and Circuit Excitability in Fragile X Syndrome
Contractor, A., Klyachko, V. A., & Portera‐Cailliau, C. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.017 · Cited by 418
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321
Self-citationAlterations of GABAergic Signaling in Autism Spectrum Disorders
Pizzarelli, R., & Cherubini, E. (2011) · Neural Plasticity · doi:10.1155/2011/297153 · Cited by 338
Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G., & Huntsman, M. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1714-10.2010 · Cited by 309
GABAergic Signaling as Therapeutic Target for Autism Spectrum Disorders
Cellot, G., & Cherubini, E. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00070 · Cited by 323
Striatal Circuits as a Common Node for Autism Pathophysiology
Fuccillo, M. V. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00027 · Cited by 269
Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance
Bozzi, Y., Provenzano, G., & Casarosa, S. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13595 · Cited by 250
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Downregulation of Tonic GABAergic Inhibition in a Mouse Model of Fragile X Syndrome
Curia, G., Papouin, T., Séguéla, P., & Avoli, M. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn159 · Cited by 218
The State of Synapses in Fragile X Syndrome
Pfeiffer, B. E., & Huber, K. M. (2009) · The Neuroscientist · doi:10.1177/1073858409333075 · Cited by 216
The role of GABAergic signalling in neurodevelopmental disorders
Tang, X., Jaenisch, R., & Sur, M. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00443-x · Cited by 221
The FXG: a presynaptic fragile X granule expressed in a subset of developing brain circuits
Christie, S. B., Akins, M. R., Schwob, J. E., & Fallon, J. R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3937-08.2009 · Cited by 208
Gatto (2010) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2010.00004 · Cited by 204
Deidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Autism genetics: searching for specificity and convergence
Berg, J. M., & Geschwind, D. H. (2012) · Genome Biology · doi:10.1186/gb-2012-13-7-247 · Cited by 192
Fragile X Syndrome: The GABAergic System and Circuit Dysfunction
Paluszkiewicz, S. M., Martin, B. S., & Huntsman, M. M. (2011) · Developmental Neuroscience · doi:10.1159/000329420 · Cited by 185
GABAergic System Dysfunction in Autism Spectrum Disorders
Zhao, H., Mao, X., Zhu, C., Zou, X., Peng, F., Yang, W., Li, B., Li, G., Ge, T., & Cui, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.781327 · Cited by 183
Neurofibromin regulates corticostriatal inhibitory networks during working memory performance
Shilyansky, C., Karlsgodt, K. H., Cummings, D. M., Sidiropoulou, K., Hardt, M. E., James, A. S., Ehninger, D., Bearden, C. E., Poirazi, P., Jentsch, J. D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004829107 · Cited by 170
Ebrahimi‐Fakhari, D., & Şahin, M. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000186 · Cited by 177
D’Hulst, C., Heulens, I., Brouwer, J. R., Willemsen, R., Geest, N. D., Reeve, S. P., Deyn, P. P. D., Hassan, B. A., & Kooy, R. F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.075 · Cited by 164
Early developmental alterations in GABAergic protein expression in fragile X knockout mice
Adusei, D. C., Pacey, L. K. K., Chen, D., & Hampson, D. R. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.002 · Cited by 139
Deng, P., Sojka, D., & Klyachko, V. A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2021-11.2011 · Cited by 139
Fatemi, S. H., Folsom, T. D., Kneeland, R. E., & Liesch, S. B. (2011) · The Anatomical Record · doi:10.1002/ar.21299 · Cited by 137
Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders
Ben‐Ari, Y. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.09.002 · Cited by 142
Pacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133
Olmos-Serrano, J. L., Corbin, J. G., & Burns, M. P. (2011) · Developmental Neuroscience · doi:10.1159/000332884 · Cited by 134
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091916 · Cited by 129
De Rubeis, S., & Bagni, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.013 · Cited by 126
Self-citationPharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model
Heulens, I., D’Hulst, C., Dam, D. V., Deyn, P. P. D., & Kooy, R. F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.031 · Cited by 125
Mechanism-based approaches to treating fragile X
Dölen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.008 · Cited by 129
Of Men and Mice: Modeling the Fragile X Syndrome
Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133
Abnormal mGlu 5 Receptor/Endocannabinoid Coupling in Mice Lacking FMRP and BC1 RNA
Maccarrone, M., Rossi, S., Bari, M., Chiara, V. D., Rapino, C., Musella, A., Bernardi, G., Bagni, C., & Centonze, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.19 · Cited by 120
Self-citationSantini, E., & Klann, E. (2014) · Science Signaling · doi:10.1126/scisignal.2005832 · Cited by 118
Zhang, Z., Marro, S. G., Zhang, Y., Arendt, K. L., Patzke, C., Zhou, B., Fair, T., Yang, N., Südhof, T. C., Wernig, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar4338 · Cited by 110
The Parvalbumin Hypothesis of Autism Spectrum Disorder
Filice, F., Janickova, L., Henzi, T., Bilella, A., & Schwaller, B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577525 · Cited by 118
FoxP1 orchestration of ASD-relevant signaling pathways in the striatum
Araujo, D. J., Anderson, A. G., Berto, S., Runnels, W., Harper, M., Ammanuel, S., Rieger, M. A., Huang, H.-C., Rajkovich, K., Loerwald, K. W., et al. (2015) · Genes & Development · doi:10.1101/gad.267989.115 · Cited by 111
The FMRP regulon: from targets to disease convergence
Fernández, E., Rajan, N., & Bagni, C. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00191 · Cited by 117
Self-citationImpaired striatal GABA transmission in experimental autoimmune encephalomyelitis
Rossi, S., Muzio, L., De Chiara, V., Grasselli, G., Musella, A., Musumeci, G., Mandolesi, G., De Ceglia, R., Maida, S., Biffi, E., et al. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.004 · Cited by 112
Self-citationDysfunction of the corticostriatal pathway in autism spectrum disorders
Li, W., & Pozzo‐Miller, L. D. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24560 · Cited by 114
Fatemi, S. H., Folsom, T. D., Rooney, R. J., & THURAS, P. D. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.46 · Cited by 94
Sciamanna, G., Bonsi, P., Tassone, A., Cuomo, D., Tscherter, A., Viscomi, M. T., Martella, G., Sharma, N., Bernardi, G., Standaert, D. G., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.001 · Cited by 90
Self-citationLauber, E., Filice, F., & Schwaller, B. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00150 · Cited by 96
Doll, C. A., & Broadie, K. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00030 · Cited by 86
Rossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
Self-citationInsights into GABAAergic system deficits in fragile X syndrome lead to clinical trials
Braat, S., & Kooy, R. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.028 · Cited by 76
Prepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment
Hessl, D. R., Berry‐Kravis, E., Cordeiro, L., Yuhas, J. M., Ornitz, E. M., Campbell, A., Chruscinski, E., Hervey, C. M., Long, J. M., & Hagerman, R. J. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30858 · Cited by 77
Impaired GABAergic inhibition in the hippocampus of Fmr1 knockout mice
Sabanov, V., Braat, S., D’Andrea, L., Willemsen, R., Zeidler, S., Rooms, L., Bagni, C., Kooy, R. F., & Balschun, D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.010 · Cited by 71
Self-citationRegulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73
Self-citationThabault, M., Turpin, V., Maïsterrena, A., Jaber, M., Egloff, M., & Galvan, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042294 · Cited by 74
Verma, V., Paul, A., Vishwanath, A. A., Vaidya, B., & Clement, J. P. (2019) · Open Biology · doi:10.1098/rsob.180265 · Cited by 68
Gomis‐González, M., Busquets-García, A., Matute, C., Maldonado, R. J., Mato, S., & Ozaita, A. (2016) · Genes · doi:10.3390/genes7090056 · Cited by 64
The non-coding RNA BC1 regulates experience-dependent structural plasticity and learning
Briz, V., Restivo, L., Pasciuto, E., Juczewski, K., Mercaldo, V., Lo, A. C., Baatsen, P., Gounko, N. V., Borreca, A., Girardi, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00311-2 · Cited by 64
Self-citationKuo, H., & Liu, F. (2019) · eNeuro · doi:10.1523/eneuro.0076-19.2019 · Cited by 65
Vislay, R. L., Martin, B. S., Olmos-Serrano, J. L., Kratovac, S., Nelson, D. L., Corbin, J. G., & Huntsman, M. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2764-12.2013 · Cited by 62
GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model
Gatto, C. L., Pereira, D. E., & Broadie, K. S. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.008 · Cited by 55
Interneuron development and dysfunction
Yang, J., Yang, X. W., & Tang, K. (2021) · FEBS Journal · doi:10.1111/febs.15872 · Cited by 54
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
Developmental Disruptions of the Dorsal Striatum in Autism Spectrum Disorder
Evans, M. M., Kim, J., Abel, T. G., Nickl‐Jockschat, T., & Stevens, H. E. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.08.015 · Cited by 56
Activity-dependent regulation of dendritic growth and maintenance by glycogen synthase kinase 3β
Rui, Y., Myers, K. R., Yu, K., Wise, A. L., Blas, A. L. D., Hartzell, H. C., & Zheng, J. Q. (2013) · Nature Communications · doi:10.1038/ncomms3628 · Cited by 52
Filippini, A., Bonini, D., Lacoux, C., Pacini, L., Zingariello, M., Sancillo, L., Bosisio, D., Salvi, V., Mingardi, J., Via, L. L., et al. (2017) · RNA Biology · doi:10.1080/15476286.2017.1338232 · Cited by 56
Self-citationMutant Mouse Models of Autism Spectrum Disorders
Provenzano, G., Zunino, G., Genovesi, S., Sgadó, P., & Bozzi, Y. (2012) · Disease Markers · doi:10.1155/2012/916082 · Cited by 53
Fragile X syndrome: From targets to treatments
Wijetunge, L. S., Chattarji, S., Wyllie, D. J. A., & Kind, P. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.028 · Cited by 54
De Rubeis, S., Fernández, E., Buzzi, A., Di Marino, D., & Bagni, C. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_23 · Cited by 48
Self-citationPacey, L. K. K., Doss, L., Cifelli, C., van der Kooy, D., Heximer, S. P., & Hampson, D. R. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.12.005 · Cited by 46
Fragile X-related protein family: a double-edged sword in neurodevelopmental disorders and cancer
Majumder, M., Johnson, R. H., & Palanisamy, V. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1810621 · Cited by 50
Dendritic protein synthesis in the normal and diseased brain
Swanger, S. A., & Bassell, G. J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.003 · Cited by 51
How Do Short-Term Changes at Synapses Fine-Tune Information Processing?
Klug, A., Borst, J. G. G., Carlson, B. A., Kopp‐Scheinpflug, C., Klyachko, V. A., & Xu‐Friedman, M. A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3348-12.2012 · Cited by 47
Fragile X Mental Retardation Protein in Learning-Related Synaptic Plasticity
Mercaldo, V., Descalzi, G., & Zhuo, M. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0193-x · Cited by 44
Self-citationLieberman, O. J., Cartocci, V., Pigulevskiy, I., Molinari, M., Carbonell, J., Broseta, M. B., Post, M. R., Sulzer, D., Borgkvist, A., & Santini, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00070 · Cited by 48
Regulatory BC1 RNA and the Fragile X Mental Retardation Protein: Convergent Functionality in Brain
Zhong, J. W., Chuang, S.-C., Bianchi, R., Zhao, W., Paul, G., Thakkar, P., Liu, D., Fenton, A. A., Wong, R. K. S., & Tiedge, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015509 · Cited by 43
Home-cage hypoactivity in mouse genetic models of autism spectrum disorder
Angelakos, C. C., Tudor, J. C., Ferri, S. L., Jongens, T. A., & Abel, T. G. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.02.010 · Cited by 44
The role of GABAergic neural circuits in the pathogenesis of autism spectrum disorder
Di, J., Li, J., O’Hara, B. F., Alberts, I. L., Xiong, L., Li, J., & Li, X. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10005 · Cited by 44
The role of GABAergic system in neurodevelopmental disorders: a focus on autism and epilepsy.
Sgadó, P., Dunleavy, M., Genovesi, S., Provenzano, G., & Bozzi, Y. (2011) · PubMed Central · Cited by 40
GABABreceptor‐mediated feed‐forward circuit dysfunction in the mouse model of fragile X syndrome
Wahlstrom‐Helgren, S., & Klyachko, V. A. (2015) · The Journal of Physiology · doi:10.1113/jp271190 · Cited by 40
Inhibition-Based Biomarkers for Autism Spectrum Disorder
Levin, A. R., & Nelson, C. A. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0350-1 · Cited by 39
Autism Spectrum Disorders and Drug Addiction: Common Pathways, Common Molecules, Distinct Disorders?
Rothwell, P. E. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00020 · Cited by 40
Imbalance of synaptic actin dynamics as a key to fragile X syndrome?
Michaelsen‐Preusse, K., Feuge, J., & Körte, M. (2018) · The Journal of Physiology · doi:10.1113/jp275571 · Cited by 36
Zhang, K., Hill, K., Labak, S., Blatt, G. J., & Soghomonian, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.020 · Cited by 36
Brandenburg, C., Soghomonian, J., Zhang, K., Sulkaj, I., Randolph, B., Kachadoorian, M., & Blatt, G. J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577858 · Cited by 37
Autism - A Neurodevelopmental Journey from Genes to Behaviour
Eapen, V. (2011) · InTech eBooks · doi:10.5772/974 · Cited by 36
Mercaldo, V., Vidimova, B., Gastaldo, D., Fernández, E., Lo, A. C., Cencelli, G., Pedini, G., Rubeis, S. D., Longo, F., Klann, E., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.008 · Cited by 32
Self-citationMolecular Biomarkers in Fragile X Syndrome
Zafarullah, M., & Tassone, F. (2019) · Brain Sciences · doi:10.3390/brainsci9050096 · Cited by 36
The neurochemical basis for the treatment of autism spectrum disorders and Fragile X syndrome
Hampson, D. R., Adusei, D. C., & Pacey, L. K. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.005 · Cited by 34
Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention
Bhogal, B., & Jongens, T. A. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.002006 · Cited by 36
Pagano, J., Landi, S., Stefanoni, A., Nardi, G., Albanesi, M., Bauer, H. F., Pracucci, E., Schön, M., Ratto, G. M., Boeckers, T. M., et al. (2023) · Molecular Autism · doi:10.1186/s13229-023-00557-2 · Cited by 38
Dysregulated Prefrontal Cortex Inhibition in Prepubescent and Adolescent Fragile X Mouse Model
Kramvis, I., van Westen, R., Lammertse, H. C. A., Riga, D., Heistek, T. S., Loebel, A., Spijker, S., Mansvelder, H. D., & Meredith, R. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00088 · Cited by 34
Fragile X syndrome and the amygdala
Suvrathan, A., & Chattarji, S. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.04.005 · Cited by 31
Fragile X syndrome: from gene discovery to therapy
Heulens, I. (2010) · Frontiers in bioscience · doi:10.2741/3785 · Cited by 32
Pharmacology, Systematic Review and Recent Clinical Trials of Metadoxine
Miceli, M. D., & Gronier, B. (2018) · Reviews on Recent Clinical Trials · doi:10.2174/1574887113666180227100217 · Cited by 30
Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement
Rosa, P. L., Petrillo, S., Bertini, E., & Piemonte, F. (2020) · Biomolecules · doi:10.3390/biom10050702 · Cited by 30
Falco, A., Pennucci, R., Brambilla, E., & de Curtis, I. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3944-7 · Cited by 29
Allegra, M., Genovesi, S., Maggia, M., Cenni, M. C., Zunino, G., Sgadó, P., Caleo, M., & Bozzi, Y. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00163 · Cited by 32
Metadata
- Authors
- Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M. T., De Chiara, V., Musella, A., Prosperetti, C., Calabresi, P., Bernardi, G., & Bagni, C.
- Affiliations
- University of Rome Tor Vergata (IT)
- University of Perugia (IT)
- ORCID
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 63
- Issue
- 10
- Pages
- 963-973
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2012460847
- Cited by
- 171
- References
- 68
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 10 · 2022: 6 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 10 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 15 · 2013: 11 · 2012: 15
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
- lirias.kuleuven.be
- Licence
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- fragile X syndrome, FMRP, BC1 RNA, striatum, GABAergic neurotransmission, inhibitory postsynaptic currents, miniature IPSCs, paired-pulse ratio, Fmr1 knockout mice, intellectual disability, synaptic plasticity
- MeSH terms
- Animals, Cerebral Cortex, Corpus Striatum, Disease Models, Animal, Electric Stimulation, Fragile X Syndrome, gamma-Aminobutyric Acid, Gene Expression Regulation, Mice, Inbred C57BL, Neural Inhibition, Synaptic Transmission, Phalloidine, Mice, Knockout, Patch-Clamp Techniques, Ribonucleoproteins, Small Cytoplasmic, RNA, Untranslated, Vesicular Inhibitory Amino Acid Transport Proteins, Mice, Fragile X Messenger Ribonucleoprotein 1, RNA, Long Noncoding, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
